The prevalence of MF/MC disease was 13.3% amongst BRCA1 mutation carriers diagnosed with breast cancer, and 47.1% amongst BRCA2 mutation carriers diagnosed with breast cancer. This evidence concerns the gene BRCA2 and breast cancer.